Summary | |
---|---|
Symbol | ITGB2 |
Name | integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) |
Aliases | MFI7; integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; macrophage antigen 1 ( ...... |
Chromosomal Location | 21q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cell membrane Single-pass type I membrane protein Membrane raft Single-pass type I membrane protein |
Domain |
PF08725 Integrin beta cytoplasmic domain PF07965 Integrin beta tail domain PF00362 Integrin beta chain VWA domain PF17205 Integrin plexin domain |
Function |
Integrin ITGAL/ITGB2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. Integrins ITGAM/ITGB2 and ITGAX/ITGB2 are receptors for the iC3b fragment of the third complement component and for fibrinogen. Integrin ITGAX/ITGB2 recognizes the sequence G-P-R in fibrinogen alpha-chain. Integrin ITGAM/ITGB2 recognizes P1 and P2 peptides of fibrinogen gamma chain. Integrin ITGAM/ITGB2 is also a receptor for factor X. Integrin ITGAD/ITGB2 is a receptor for ICAM3 and VCAM1. Contributes to natural killer cell cytotoxicity (PubMed:15356110). Involved in leukocyte adhesion and transmigration of leukocytes including T-cells and neutrophils (PubMed:11812992, PubMed:28807980). Triggers neutrophil transmigration during lung injury through PTK2B/PYK2-mediated activation (PubMed:18587400). Integrin ITGAL/ITGB2 in association with ICAM3, contributes to apoptotic neutrophil phagocytosis by macrophages (PubMed:23775590). In association with alpha subunit ITGAM/CD11b, required for CD177-PRTN3-mediated activation of TNF primed neutrophils (PubMed:21193407). |
Biological Process |
GO:0001525 angiogenesis GO:0001667 ameboidal-type cell migration GO:0001704 formation of primary germ layer GO:0001706 endoderm formation GO:0002218 activation of innate immune response GO:0002221 pattern recognition receptor signaling pathway GO:0002224 toll-like receptor signaling pathway GO:0002523 leukocyte migration involved in inflammatory response GO:0002757 immune response-activating signal transduction GO:0002758 innate immune response-activating signal transduction GO:0002764 immune response-regulating signaling pathway GO:0006809 nitric oxide biosynthetic process GO:0006898 receptor-mediated endocytosis GO:0006909 phagocytosis GO:0007159 leukocyte cell-cell adhesion GO:0007160 cell-matrix adhesion GO:0007229 integrin-mediated signaling pathway GO:0007369 gastrulation GO:0007492 endoderm development GO:0007568 aging GO:0008360 regulation of cell shape GO:0010631 epithelial cell migration GO:0018108 peptidyl-tyrosine phosphorylation GO:0018212 peptidyl-tyrosine modification GO:0022604 regulation of cell morphogenesis GO:0030101 natural killer cell activation GO:0030198 extracellular matrix organization GO:0030593 neutrophil chemotaxis GO:0030595 leukocyte chemotaxis GO:0031349 positive regulation of defense response GO:0031589 cell-substrate adhesion GO:0031623 receptor internalization GO:0034113 heterotypic cell-cell adhesion GO:0034142 toll-like receptor 4 signaling pathway GO:0035987 endodermal cell differentiation GO:0043062 extracellular structure organization GO:0043112 receptor metabolic process GO:0043113 receptor clustering GO:0043542 endothelial cell migration GO:0045088 regulation of innate immune response GO:0045089 positive regulation of innate immune response GO:0045123 cellular extravasation GO:0045428 regulation of nitric oxide biosynthetic process GO:0045429 positive regulation of nitric oxide biosynthetic process GO:0045765 regulation of angiogenesis GO:0045766 positive regulation of angiogenesis GO:0046209 nitric oxide metabolic process GO:0048514 blood vessel morphogenesis GO:0050730 regulation of peptidyl-tyrosine phosphorylation GO:0050900 leukocyte migration GO:0051090 regulation of sequence-specific DNA binding transcription factor activity GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051092 positive regulation of NF-kappaB transcription factor activity GO:0051668 localization within membrane GO:0055094 response to lipoprotein particle GO:0055098 response to low-density lipoprotein particle GO:0060326 cell chemotaxis GO:0071402 cellular response to lipoprotein particle stimulus GO:0071404 cellular response to low-density lipoprotein particle stimulus GO:0071621 granulocyte chemotaxis GO:0072593 reactive oxygen species metabolic process GO:0072657 protein localization to membrane GO:0090130 tissue migration GO:0090132 epithelium migration GO:0097529 myeloid leukocyte migration GO:0097530 granulocyte migration GO:1901342 regulation of vasculature development GO:1903409 reactive oxygen species biosynthetic process GO:1903426 regulation of reactive oxygen species biosynthetic process GO:1903428 positive regulation of reactive oxygen species biosynthetic process GO:1904018 positive regulation of vasculature development GO:1904407 positive regulation of nitric oxide metabolic process GO:1990266 neutrophil migration GO:2000377 regulation of reactive oxygen species metabolic process GO:2000379 positive regulation of reactive oxygen species metabolic process GO:2001057 reactive nitrogen species metabolic process |
Molecular Function |
GO:0001948 glycoprotein binding GO:0030369 ICAM-3 receptor activity GO:0046982 protein heterodimerization activity GO:0050839 cell adhesion molecule binding |
Cellular Component |
GO:0008305 integrin complex GO:0034687 integrin alphaL-beta2 complex GO:0043235 receptor complex GO:0098636 protein complex involved in cell adhesion GO:0098802 plasma membrane receptor complex |
KEGG |
hsa04015 Rap1 signaling pathway hsa04145 Phagosome hsa04390 Hippo signaling pathway hsa04514 Cell adhesion molecules (CAMs) hsa04610 Complement and coagulation cascades hsa04650 Natural killer cell mediated cytotoxicity hsa04670 Leukocyte transendothelial migration hsa04810 Regulation of actin cytoskeleton |
Reactome |
R-HSA-1280218: Adaptive Immune System R-HSA-202733: Cell surface interactions at the vascular wall R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-1474244: Extracellular matrix organization R-HSA-109582: Hemostasis R-HSA-168256: Immune System R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell R-HSA-168249: Innate Immune System R-HSA-216083: Integrin cell surface interactions R-HSA-6785807: Interleukin-4 and 13 signaling R-HSA-6798695: Neutrophil degranulation R-HSA-449147: Signaling by Interleukins R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade R-HSA-168898: Toll-Like Receptors Cascades |
Summary | |
---|---|
Symbol | ITGB2 |
Name | integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) |
Aliases | MFI7; integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; macrophage antigen 1 ( ...... |
Chromosomal Location | 21q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between ITGB2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between ITGB2 and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | ITGB2 |
Name | integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) |
Aliases | MFI7; integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; macrophage antigen 1 ( ...... |
Chromosomal Location | 21q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of ITGB2 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | ITGB2 |
Name | integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) |
Aliases | MFI7; integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; macrophage antigen 1 ( ...... |
Chromosomal Location | 21q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of ITGB2 in various data sets.
|
Points in the above scatter plot represent the mutation difference of ITGB2 in various data sets.
|
Summary | |
---|---|
Symbol | ITGB2 |
Name | integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) |
Aliases | MFI7; integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; macrophage antigen 1 ( ...... |
Chromosomal Location | 21q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ITGB2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | ITGB2 |
Name | integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) |
Aliases | MFI7; integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; macrophage antigen 1 ( ...... |
Chromosomal Location | 21q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ITGB2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ITGB2. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | ITGB2 |
Name | integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) |
Aliases | MFI7; integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; macrophage antigen 1 ( ...... |
Chromosomal Location | 21q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ITGB2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | ITGB2 |
Name | integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) |
Aliases | MFI7; integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; macrophage antigen 1 ( ...... |
Chromosomal Location | 21q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of ITGB2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | ITGB2 |
Name | integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) |
Aliases | MFI7; integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; macrophage antigen 1 ( ...... |
Chromosomal Location | 21q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between ITGB2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | ITGB2 |
Name | integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) |
Aliases | MFI7; integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; macrophage antigen 1 ( ...... |
Chromosomal Location | 21q22.3 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting ITGB2 collected from DrugBank database. |
Details on drugs targeting ITGB2.
|